RNA Therapy Clinical Trials Market to Grow with a CAGR of 5.73% through 2030
The rising growing prevalence of genetic diseases are expected to drive
the Global RNA Therapy Clinical Trials Market in the forecast period 2026-2030.
According to TechSci Research report, “RNA Therapy Clinical Trials Market –Global Industry Size, Share, Trends, Competition,
Opportunity and Forecast, 2030F”, the Global
RNA Therapy Clinical Trials Market stood at USD 2.87 billion in 2024 and is
anticipated to project robust growth in the forecast period with a CAGR of 5.73%
through 2030. This phenomenon can be attributed to the cooperative efforts and
alliances formed by prominent businesses, which employ a varied strategy to
combine the specialized knowledge of each company, thereby enhancing their
market presence. Additionally, the recent advancements and developments of niche
technologies are expected to propell the growth of Global RNA Therapy Clinical
Trials Market by launches of new therapies for different applications, rising
government initiatives, etc are expected to rise the growth of Global RNA
Therapy Clinical Trials Market.
RNA Therapy Clinical Trials hold significant
promise across a spectrum of medical applications, offering innovative
approaches to address a wide range of diseases and conditions. The versatility
and precision of RNA-based therapies have sparked growing interest and research
efforts in various therapeutic areas within the field of clinical trials. RNA
Therapy Clinical Trials are revolutionizing cancer treatment by targeting
specific genetic mutations or overexpressed genes that drive tumor growth. mRNA
vaccines and siRNA therapies are being explored to inhibit the expression of
oncogenes, while immunomodulatory RNA therapies aim to enhance the body's
immune response against cancer cells. These therapies have the potential to be
more selective, less toxic, and more adaptable to tumor heterogeneity compared
to traditional chemotherapy. RNA therapies hold promise for treating genetic
disorders caused by single gene mutations, such as cystic fibrosis, muscular
dystrophy, and Huntington's disease. ASOs can be designed to correct abnormal
gene splicing patterns or promote the degradation of disease-causing RNA
molecules, offering a potential avenue to address the root causes of these
conditions.
RNA Therapy Clinical Trials are exploring treatments for
neurodegenerative disorders like Alzheimer's, Parkinson's, and amyotrophic
lateral sclerosis (ALS). ASOs and other RNA molecules are designed to target
genes associated with disease progression, potentially slowing down or halting
degeneration and providing neuroprotection. RNA therapies have garnered
attention due to the success of mRNA vaccines against infectious diseases like
COVID-19. Beyond vaccines, RNA Therapy Clinical Trials are investigating
antiviral siRNA therapies that inhibit viral replication, offering potential
treatments for HIV, hepatitis B, and respiratory viruses. Many rare diseases
lack effective treatments.
RNA Therapy Clinical Trials are exploring
personalized approaches to target specific genetic mutations underlying these
conditions. This includes disorders like Duchenne muscular dystrophy,
phenylketonuria (PKU), and rare genetic metabolic disorders. RNA therapies are
being investigated as potential treatments for cardiovascular diseases such as
heart failure and hypercholesterolemia. mRNA therapies can stimulate the
production of beneficial proteins, while siRNA therapies can silence genes
associated with cholesterol metabolism. RNA-based therapies offer the
possibility of modulating immune responses in autoimmune diseases like
rheumatoid arthritis, multiple sclerosis, and lupus. By targeting
immune-related genes or inflammatory pathways, these therapies aim to restore
immune balance and mitigate disease symptoms. However, the preference for appropriate technology,
competitive market landscape and growing concerns for human health are expected
to slow down the growth of the Global RNA Therapy Clinical Trials Market in the
coming years.
Browse over XX market data Figures and spread through XX Pages and an in-depth TOC on "Global RNA Therapy Clinical Trials Market.”
The Global RNA Therapy Clinical Trials Market segmentation
is based on Modality, Phase, Therapeutic Areas, Company, and Region.
Based on the therapeutic areas, The rare disease segment is emerging as the fastest-growing category in the RNA Therapy Clinical Trials Market, driven by increasing research initiatives and investments in orphan drug development. With over 7,000 rare diseases affecting millions worldwide and limited treatment options available, there is a strong demand for innovative RNA-based therapies. Governments and regulatory agencies, including the FDA and EMA, are offering incentives such as orphan drug designations, fast-track approvals, and extended market exclusivity, encouraging biotech firms to invest in RNA therapies for rare diseases. Additionally, advancements in mRNA, siRNA, and antisense oligonucleotide technologies have significantly enhanced the feasibility of developing targeted treatments for genetic and metabolic disorders. The rise in strategic partnerships between pharmaceutical companies and biotech startups has further accelerated clinical trials in this segment. For instance, companies like Moderna, Ionis Pharmaceuticals, and Alnylam Pharmaceuticals are actively working on RNA-based treatments for conditions such as spinal muscular atrophy (SMA), Duchenne muscular dystrophy (DMD), and amyloidosis.
Based on the region, The Asia-Pacific region is experiencing the fastest growth in the RNA Therapy Clinical Trials Market, driven by increasing government support, rising investments in biotechnology, and a growing prevalence of rare diseases. Countries like China, Japan, South Korea, and India are rapidly expanding their capabilities in RNA-based drug development through research funding, regulatory advancements, and strategic collaborations. The region benefits from a large patient pool, making it an attractive location for conducting clinical trials at a lower cost compared to Western countries. Additionally, faster regulatory approvals and initiatives like China's regulatory reforms for innovative drugs and Japan's Sakigake fast-track approval system are encouraging global pharmaceutical companies to expand their RNA therapy research in Asia-Pacific.
Some of the major companies operating in the Global
RNA Therapy Clinical Trials Market include:
- IQVIA
Inc.
- ICON
Plc
- Laboratory
Corporation of America Holdings
- Charles
River Laboratories International, Inc.
- PAREXEL
International Corp.
- Syneos
Health
- Medpace
Holdings, Inc.
- Novotech
Inc.
- PPD Inc.
- Veristat,
LLC.
Download Free Sample Report
Customers can
also request for 10% free customization on this report.
“North America was expected to dominate in the RNA
Therapy Clinical Trials Market due to the presence of many pharmaceutical and
biotechnology companies in the region, as well as significant government
funding for research and development in the life sciences. Similarly, these
technologies are critical for developing new treatments and therapies along
with the growing prevalence of chronic diseases such as cancer is expected to
create lucrative growth in the market during the forecast period. Also, growing
government funding for healthcare infrastructure and a large and rapidly expanding
population is expected to drive the growth of the market during the forecast
period", said Mr. Karan Chechi, Research Director of TechSci Research, a
research-based Global management consulting firm.
"RNA Therapy Clinical Trials Market - Global Industry Size, Share,
Trends, Competition, Opportunity, and Forecast, Segmented By Product (Small Molecule API, Small Molecule Drug Product),
By Stage Type (Preclinical, Clinical, Commercial), By Customer Type
(Pharmaceutical, Biotechnology), By Therapeutic Area (Cardiovascular disease,
Oncology, Respiratory disorders, Neurology, Metabolic disorders, Infectious
disease, Others), By Region and Competition, 2020-2030F", has evaluated the future growth potential of Global
RNA Therapy Clinical Trials Market and provides statistics & information on
market size, structure, and future market growth. The report intends to provide
innovative market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global RNA
Therapy Clinical Trials Market.
Contact Us-
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
M: +13322586602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com